192 related articles for article (PubMed ID: 27286460)
1. Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma.
Wang L; Pan L; Yao M; Cai Y; Dong Z; Yao D
Oncotarget; 2016 Jul; 7(27):42150-42158. PubMed ID: 27286460
[TBL] [Abstract][Full Text] [Related]
2. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma.
Yao M; Wang L; Fang M; Zheng W; Dong Z; Yao D
Biosci Trends; 2016 Nov; 10(5):337-343. PubMed ID: 27795482
[TBL] [Abstract][Full Text] [Related]
3. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.
Wang L; Yao M; Pan LH; Qian Q; Yao DF
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):361-6. PubMed ID: 26256079
[TBL] [Abstract][Full Text] [Related]
5. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.
Yao M; Yao DF; Bian YZ; Zhang CG; Qiu LW; Wu W; Sai WL; Yang JL; Zhang HJ
Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):289-94. PubMed ID: 21669573
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation.
Cui X; Li Z; Gao PJ; Gao J; Zhu JY
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):157-63. PubMed ID: 25865688
[TBL] [Abstract][Full Text] [Related]
7. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.
Sideras K; Bots SJ; Biermann K; Sprengers D; Polak WG; IJzermans JN; de Man RA; Pan Q; Sleijfer S; Bruno MJ; Kwekkeboom J
Br J Cancer; 2015 Jun; 112(12):1911-20. PubMed ID: 26057582
[TBL] [Abstract][Full Text] [Related]
8. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ
World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561
[TBL] [Abstract][Full Text] [Related]
9. Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.
Hong B; Qian Y; Zhang H; Sang YW; Cheng LF; Wang Q; Gao S; Zheng M; Yao HP
World J Gastroenterol; 2016 May; 22(18):4538-46. PubMed ID: 27182163
[TBL] [Abstract][Full Text] [Related]
10. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].
Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD
Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223
[TBL] [Abstract][Full Text] [Related]
11. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.
Wang JY; Wang XK; Zhu GZ; Zhou X; Yao J; Ma XP; Wang B; Peng T
BMC Cancer; 2021 Apr; 21(1):462. PubMed ID: 33902495
[TBL] [Abstract][Full Text] [Related]
12. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma.
Yao M; Yao DF; Bian YZ; Wu W; Yan XD; Yu DD; Qiu LW; Yang JL; Zhang HJ; Sai WL; Chen J
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):171-9. PubMed ID: 23558072
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of PUMA expression in patients with HBV-related hepatocellular carcinoma.
Peng SL; Yao DB; Zhao Y; Xu F; Jia CJ; Xu YQ; Dai CL
Eur Rev Med Pharmacol Sci; 2015 Jan; 19(1):38-44. PubMed ID: 25635973
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
Dong ZZ; Yao DF; Yao M; Qiu LW; Zong L; Wu W; Wu XH; Yao DB; Meng XY
Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):288-95. PubMed ID: 18522884
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma.
Yao M; Zhao J; Lu F
Oncotarget; 2016 Jan; 7(4):3702-8. PubMed ID: 26784252
[TBL] [Abstract][Full Text] [Related]
18. Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma.
Dong Z; Yao M; Wang L; Yang J; Yao D
Mini Rev Med Chem; 2014; 14(14):1183-93. PubMed ID: 25553423
[TBL] [Abstract][Full Text] [Related]
19. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry.
Mu H; Lin KX; Zhao H; Xing S; Li C; Liu F; Lu HZ; Zhang Z; Sun YL; Yan XY; Cai JQ; Zhao XH
World J Gastroenterol; 2014 May; 20(19):5826-38. PubMed ID: 24914343
[TBL] [Abstract][Full Text] [Related]
20. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.
Xia L; Huang W; Tian D; Zhu H; Zhang Y; Hu H; Fan D; Nie Y; Wu K
J Hepatol; 2012 Sep; 57(3):600-12. PubMed ID: 22613004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
